Alan S Go1,2,3,4, Thida C Tan5, Glenn M Chertow4, Juan D Ordonez6, Dongjie Fan5, David Law6, Leonid Yankulin7, Janet M Wojcicki3,8, Sijie Zheng6, Kenneth K Chen6, Farzien Khoshniat-Rad5, Jingrong Yang5, Rishi V Parikh5. 1. Division of Research, Kaiser Permanente Northern California, Oakland, California Alan.S.Go@kp.org. 2. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California. 3. Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco, San Francisco, California. 4. Department of Medicine, Stanford University School of Medicine, Stanford, California. 5. Division of Research, Kaiser Permanente Northern California, Oakland, California. 6. Department of Nephrology, Kaiser Permanente East Bay, Oakland, California. 7. Department of Nephrology, Kaiser Permanente San Francisco Medical Center, Oakland, California. 8. Department of Pediatrics, University of California, San Francisco, San Francisco, California.
Abstract
BACKGROUND: Little population-based data exist about adults with primary nephrotic syndrome. METHODS: To evaluate kidney, cardiovascular, and mortality outcomes in adults with primary nephrotic syndrome, we identified adults within an integrated health care delivery system (Kaiser Permanente Northern California) with nephrotic-range proteinuria or diagnosed nephrotic syndrome between 1996 and 2012. Nephrologists reviewed medical records for clinical presentation, laboratory findings, and biopsy results to confirm primary nephrotic syndrome and assigned etiology. We identified a 1:100 time-matched cohort of adults without diabetes, diagnosed nephrotic syndrome, or proteinuria as controls to compare rates of ESKD, cardiovascular outcomes, and death through 2014, using multivariable Cox regression. RESULTS: We confirmed 907 patients with primary nephrotic syndrome (655 definite and 252 presumed patients with FSGS [40%], membranous nephropathy [40%], and minimal change disease [20%]). Mean age was 49 years; 43% were women. Adults with primary nephrotic syndrome had higher adjusted rates of ESKD (adjusted hazard ratio [aHR], 19.63; 95% confidence interval [95% CI], 12.76 to 30.20), acute coronary syndrome (aHR, 2.58; 95% CI, 1.89 to 3.52), heart failure (aHR, 3.01; 95% CI, 2.16 to 4.19), ischemic stroke (aHR, 1.80; 95% CI, 1.06 to 3.05), venous thromboembolism (aHR, 2.56; 95% CI, 1.35 to 4.85), and death (aHR, 1.34; 95% CI, 1.09 to 1.64) versus controls. Excess ESKD risk was significantly higher for FSGS and membranous nephropathy than for presumed minimal change disease. The three etiologies of primary nephrotic syndrome did not differ significantly in terms of cardiovascular outcomes and death. CONCLUSIONS: Adults with primary nephrotic syndrome experience higher adjusted rates of ESKD, cardiovascular outcomes, and death, with significant variation by underlying etiology in the risk for developing ESKD.
BACKGROUND: Little population-based data exist about adults with primary nephrotic syndrome. METHODS: To evaluate kidney, cardiovascular, and mortality outcomes in adults with primary nephrotic syndrome, we identified adults within an integrated health care delivery system (Kaiser Permanente Northern California) with nephrotic-range proteinuria or diagnosed nephrotic syndrome between 1996 and 2012. Nephrologists reviewed medical records for clinical presentation, laboratory findings, and biopsy results to confirm primary nephrotic syndrome and assigned etiology. We identified a 1:100 time-matched cohort of adults without diabetes, diagnosed nephrotic syndrome, or proteinuria as controls to compare rates of ESKD, cardiovascular outcomes, and death through 2014, using multivariable Cox regression. RESULTS: We confirmed 907 patients with primary nephrotic syndrome (655 definite and 252 presumed patients with FSGS [40%], membranous nephropathy [40%], and minimal change disease [20%]). Mean age was 49 years; 43% were women. Adults with primary nephrotic syndrome had higher adjusted rates of ESKD (adjusted hazard ratio [aHR], 19.63; 95% confidence interval [95% CI], 12.76 to 30.20), acute coronary syndrome (aHR, 2.58; 95% CI, 1.89 to 3.52), heart failure (aHR, 3.01; 95% CI, 2.16 to 4.19), ischemic stroke (aHR, 1.80; 95% CI, 1.06 to 3.05), venous thromboembolism (aHR, 2.56; 95% CI, 1.35 to 4.85), and death (aHR, 1.34; 95% CI, 1.09 to 1.64) versus controls. Excess ESKD risk was significantly higher for FSGS and membranous nephropathy than for presumed minimal change disease. The three etiologies of primary nephrotic syndrome did not differ significantly in terms of cardiovascular outcomes and death. CONCLUSIONS: Adults with primary nephrotic syndrome experience higher adjusted rates of ESKD, cardiovascular outcomes, and death, with significant variation by underlying etiology in the risk for developing ESKD.
Authors: Rutger J Maas; Jeroen K Deegens; Johan R Beukhof; Louis J Reichert; Marc A Ten Dam; Jaap J Beutler; A Warmold L van den Wall Bake; Pieter L Rensma; Constantijn J Konings; Daniel A Geerse; Geert W Feith; Willi H Van Kuijk; Jack F Wetzels Journal: Am J Kidney Dis Date: 2017-01-12 Impact factor: 8.860
Authors: Sean J Barbour; Allen Greenwald; Ognjenka Djurdjev; Adeera Levin; Michelle A Hladunewich; Patrick H Nachman; Susan L Hogan; Daniel C Cattran; Heather N Reich Journal: Kidney Int Date: 2011-09-14 Impact factor: 10.612
Authors: Lowell J Lo; Alan S Go; Glenn M Chertow; Charles E McCulloch; Dongjie Fan; Juan D Ordoñez; Chi-yuan Hsu Journal: Kidney Int Date: 2009-07-29 Impact factor: 10.612
Authors: Crystal A Gadegbeku; Debbie S Gipson; Lawrence B Holzman; Akinlolu O Ojo; Peter X K Song; Laura Barisoni; Matthew G Sampson; Jeffrey B Kopp; Kevin V Lemley; Peter J Nelson; Chrysta C Lienczewski; Sharon G Adler; Gerald B Appel; Daniel C Cattran; Michael J Choi; Gabriel Contreras; Katherine M Dell; Fernando C Fervenza; Keisha L Gibson; Larry A Greenbaum; Joel D Hernandez; Stephen M Hewitt; Sangeeta R Hingorani; Michelle Hladunewich; Marie C Hogan; Susan L Hogan; Frederick J Kaskel; John C Lieske; Kevin E C Meyers; Patrick H Nachman; Cynthia C Nast; Alicia M Neu; Heather N Reich; John R Sedor; Christine B Sethna; Howard Trachtman; Katherine R Tuttle; Olga Zhdanova; Gastòn E Zilleruelo; Matthias Kretzler Journal: Kidney Int Date: 2013-01-16 Impact factor: 10.612
Authors: Martina Tedesco; Federica Mescia; Isabella Pisani; Marco Allinovi; Giovanni Casazza; Lucia Del Vecchio; Marisa Santostefano; Luigi Cirillo; Francesca Ferrario; Ciro Esposito; Pasquale Esposito; Domenico Santoro; Roberta Lazzarin; Giovanni Maria Rossi; Enrico Fiaccadori; Angelo Ferrantelli; Renato Alberto Sinico; Mario Cozzolino; Maurizio Gallieni; Lino Cirami; Francesco Scolari; Augusto Vaglio; Federico Alberici Journal: Kidney Int Rep Date: 2022-05-30
Authors: Jonathan de Fallois; Soeren Schenk; Jan Kowald; Tom H Lindner; Marie Engesser; Johannes Münch; Christof Meigen; Jan Halbritter Journal: PLoS One Date: 2022-09-02 Impact factor: 3.752